Pfizer Net Profit Margin 2010-2022 | PFE

Current and historical net profit margin for Pfizer (PFE) from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue. Pfizer net profit margin for the three months ending March 31, 2022 was .
Pfizer Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $92.43B $24.97B 27.01%
2021-12-31 $81.29B $21.98B 27.04%
2021-09-30 $69.01B $19.43B 28.16%
2021-06-30 $55.20B $12.76B 23.11%
2021-03-31 $46.08B $10.68B 23.18%
2020-12-31 $41.65B $9.16B 21.99%
2020-09-30 $32.07B $7.73B 24.10%
2020-06-30 $34.47B $13.94B 40.44%
2020-03-31 $37.87B $15.50B 40.92%
2019-12-31 $40.91B $16.03B 39.18%
2019-09-30 $40.22B $16.22B 40.32%
2019-06-30 $40.84B $12.65B 30.98%
2019-03-31 $41.04B $11.48B 27.97%
2018-12-31 $40.83B $11.15B 27.32%
2018-09-30 $53.37B $23.82B 44.63%
2018-06-30 $53.24B $22.55B 42.35%
2018-03-31 $52.67B $21.75B 41.29%
2017-12-31 $52.55B $21.31B 40.55%
2017-09-30 $52.47B $9.81B 18.69%
2017-06-30 $52.35B $8.32B 15.90%
2017-03-31 $52.60B $7.30B 13.88%
2016-12-31 $52.82B $7.22B 13.66%
2016-09-30 $53.24B $6.27B 11.77%
2016-06-30 $52.29B $7.04B 13.47%
2016-03-31 $50.99B $7.62B 14.95%
2015-12-31 $48.85B $6.96B 14.25%
2015-09-30 $47.92B $8.36B 17.45%
2015-06-30 $48.20B $8.90B 18.46%
2015-03-31 $49.12B $9.18B 18.69%
2014-12-31 $49.61B $9.14B 18.42%
2014-09-30 $50.05B $10.48B 20.93%
2014-06-30 $50.33B $10.40B 20.66%
2014-03-31 $50.53B $21.58B 42.71%
2013-12-31 $51.58B $22.00B 42.65%
2013-09-30 $50.88B $25.75B 50.61%
2013-06-30 $51.19B $26.37B 51.51%
2013-03-31 $52.18B $15.53B 29.75%
2012-12-31 $54.66B $14.57B 26.66%
2012-09-30 $53.25B $9.69B 18.21%
2012-06-30 $56.90B $10.22B 17.97%
2012-03-31 $59.42B $9.58B 16.12%
2011-12-31 $61.04B $10.01B 16.40%
2011-09-30 $65.06B $11.46B 17.62%
2011-06-30 $64.44B $8.59B 13.33%
2011-03-31 $65.09B $8.45B 12.99%
2010-12-31 $65.17B $8.26B 12.67%
2010-09-30 $65.50B $6.13B 9.36%
2010-06-30 $61.13B $8.15B 13.33%
2010-03-31 $54.98B $7.93B 14.43%
2009-12-31 $49.27B $8.64B 17.53%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $280.096B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.363B 17.90
Eli Lilly (LLY) United States $277.095B 32.69
AbbVie (ABBV) United States $271.251B 11.89
Merck (MRK) United States $228.629B 12.92
Novartis AG (NVS) Switzerland $191.957B 13.82
GlaxoSmithKline (GSK) United Kingdom $110.111B 12.85
Novo Nordisk (NVO) Denmark $0.000B 31.56